John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 50,000 shares at $24.51 ($1.2M) on 2025-10-01, disclosed to the SEC on 2025-10-03.
Scheduled sale ($1.2M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.51 | 25,000 | $613K | 49.9% |
| 2 | $24.63 | 25,000 | $616K | 50.1% |
| Total | $24.57 avg | 50,000 | $1.2M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-04-03 | $1.1M | — | Filing → |